CapsoVision (NASDAQ: CV) Stock Rockets After-Hours: Price Action, Q3 Earnings and 2026 Outlook

Published: December 11, 2025

CapsoVision, Inc. (NASDAQ: CV) has suddenly moved from a quiet post‑IPO med‑tech name to one of the most volatile small caps on the market. On Wednesday, December 10, the stock closed at $11.80, up 32.73% on the day, then surged another 52.9% in after‑hours trading to $18.04, according to Benzinga and RTTNews. ^[1]

The move caps a remarkable run for the capsule endoscopy specialist, whose AI‑enabled gastrointestinal imaging platform is now drawing intense attention despite continuing losses and a valuation far above current analyst price targets.

CapsoVision stock price today: from micro‑cap listing to high‑beta mover

Multiple real‑time data providers show CapsoVision closing regular trading on December 10 at $11.80, with the shares up more than 109% over the past week and about 146% over the past month. ^[2]

Key trading metrics as of the latest data:

Last regular close: $11.80 (Dec 10) ^[3]
After‑hours high: $18.04 (Dec 10) ^[4]
52‑week range: roughly $3.43 – $11.80 so far, with the latest close at the top of that band. ^[5]
Market capitalization: about $552.8 million at $11.80 per share. ^[6]
Volatility: average weekly price movement ~13–14%, and daily swings above 30% this week. ^[7]

Pre‑market data on December 11 show some profit‑taking, with the stock quoted around $9.71, down ~17.7% versus Wednesday’s close. ^[8] This pattern—sharp intraday spikes followed by fast reversals—is typical of low‑float, story‑driven small caps.

Why did CapsoVision spike? Volume, narrative, and a slow‑burn catalyst

Explosive trading activity

A December 10 article on Sete News noted that 0.56 million CapsoVision shares changed hands in one recent session, far above an average volume of roughly 35,000 shares. On that day, the stock traded between $7.32 and $11.00 and was already up more than 60% over the week and nearly 88% over the prior month. ^[9]

RTTNews then highlighted an even more dramatic session: on December 10 the stock closed at $11.80, up 32.73%, with 1.7 million shares traded versus an average of about 44,000; after hours, it climbed again to $18.04. ^[10]

The float appears relatively constrained. One recent breakdown put shares outstanding at 46.8 million and the freely tradable float at about 28.7 million, with short interest of around 37,700 shares as of mid‑November. ^[11] A float of that size combined with spiking volume is fertile ground for momentum traders and short squeezes.

Leadership story resurfacing

Benzinga’s late‑evening piece on December 10 tied the after‑hours surge in part to renewed attention on CapsoVision’s new finance chief, David Garcia, appointed Senior Vice President of Finance effective November 3. ^[12]

Garcia previously held senior finance roles at:

Matterport (helping shepherd its IPO)
View Inc.
Intelepeer Cloud Communications
Align Technology (NASDAQ: ALGN)

He earlier worked at Oracle and Deloitte and holds an MBA in Finance from Wharton and a BA in Economics from Stanford. ^[13]

While that appointment is more than a month old, traders often “rediscover” older catalysts when a stock starts to move. In this case, the Garcia hire adds a professional capital‑markets profile to a company that went public only in July.

Growing visibility with investors

CapsoVision also stepped up its investor‑relations efforts. On December 4, senior management—including CEO Johnny Wang, Garcia, and Head of Global Sales Doug Atkinson—participated in the Benchmark 14th Annual Discovery One‑on‑One Investor Conference in New York. ^[14]

A December 9 MarketBeat article flagged CapsoVision as trading 51% higher in a single session, with the stock hitting $10.99 on 32% above‑average volume and vaulting far above its 50‑day moving average. ^[15] That piece framed CV as a speculative, momentum‑driven small cap whose fundamentals are still catching up with price.

Business snapshot: AI‑enabled capsule endoscopy

RTTNews and the company’s own filings paint a picture of a focused med‑tech platform: ^[16]

Core product – CapsoCam Plus®
A wire‑free capsule endoscope that provides panoramic imaging of the small bowel for conditions such as obscure GI bleeding and Crohn’s disease. Approved for adults and children aged 2+.
Pipeline – CapsoCam Colon™ and CapsoColon 3D
Next‑generation capsules aimed at non‑invasive colon imaging and polyp detection, and a future 3D colon capsule for comprehensive large‑intestine visualization.
Software ecosystem
- CapsoCloud – cloud‑based SaaS for off‑premises video access and retrieval.
- CapsoAccess – capsule data access system.
- CapsoView – dedicated viewer for capsule videos.
- CapsoRetrieve – a magnetic retrieval kit to recover the capsule after it passes.

This integrated “capsule + cloud + AI analytics” story is part of why CV has attracted AI‑themed investors despite its relatively small revenue base.

Q3 2025 results: solid growth, heavy losses

CapsoVision reported third‑quarter 2025 results on November 13. The headline numbers: ^[17]

Revenue: $3.54 million (up 19% year‑over‑year from $2.97m).
Gross margin:54%, slightly down from 56% a year earlier.
Operating expenses:$9.93 million, up from $7.46m, driven by R&D spending on a new CMOS sensor with Canon and higher public‑company costs.
Operating loss:–$8.02 million.
Net loss:–$7.92 million, or –$0.17 per share, versus –$5.79m a year earlier.
Cash and cash equivalents:$17.8 million at September 30.

TradingView and MarketBeat both note that Q3 missed consensus estimates, with EPS at –$0.17 versus an expected –$0.12 and revenue of roughly $3.54m versus a ~$3.67m estimate. ^[18]

Over the trailing twelve months, CapsoVision has generated about $13.1 million of revenue and a net loss of roughly $22.6 million, implying a net margin around –172% and a price‑to‑sales ratio above 40x at recent prices. ^[19]

Strategic and clinical pipeline: pancreatic cancer and beyond

Management is trying to justify that valuation by leaning hard into new indications and AI‑driven products:

Breakthrough Device Designation application (pancreatic cancer)
On November 10, CapsoVision announced it had submitted an application to the FDA for Breakthrough Device Designation for an endoscopy capsule aimed at early‑stage pancreatic cancer detection, targeting a cancer with 5‑year survival rates in the high single digits and very limited screening options today. ^[20]
Canon partnership
The company entered an agreement with Canon Inc. to develop higher‑resolution CMOS image sensors with enhanced dynamic range for future capsule devices. ^[21]
Colon capsule clinical study
CapsoVision has begun enrollment in a clinical study for its next‑generation colon capsule, working closely with the FDA to advance a non‑invasive colon‑screening option. ^[22]

As of the end of Q3, management reported that CapsoCam Plus had been used by more than 151,000 patients, a sign that adoption, while still niche, is expanding. ^[23]

Analyst forecasts and price targets: consensus still around $6

While the stock has sprinted well above its IPO price and prior highs, analyst models have not moved nearly as fast.

Across several data providers, the 12‑month price‑target consensus clusters around $6 per share:

MarketBeat: 4 analysts, average target $6.00, range $5–7, implying roughly 49% downside from $11.80. ^[24]
Investing.com consensus: 2 analysts, “Strong Buy” rating with average target $6, high $7, low $5. ^[25]
Zacks: short‑term targets from two analysts also average about $6.00. ^[26]
Nasdaq/Fintel note (Nov 16): average one‑year price target raised from $5.10 to $6.12, a 20% increase as coverage deepened. ^[27]
TradingView forecast page: confirms a max estimate of $7 and min of $5, with next‑quarter EPS expected at –$0.14 and revenue around $4.3 million. ^[28]

Several firms have initiated or reiterated coverage since the IPO:

Roth Capital: Buy rating, target $6 (with other notes referencing a $7 target in some early research). ^[29]
Benchmark: “Speculative Buy” rating, target $5. ^[30]
Weiss Ratings: more cautious, with a Sell‑equivalent rating cited in MarketBeat’s December 9 note. ^[31]

In other words, while most sell‑side shops like the long‑term story and label CV at least a buy or speculative buy, their models still assume a fair value roughly half the current price.

Independent fundamental analysis: growth vs. valuation

Simply Wall St’s quantitative model illustrates the tension between growth expectations and current valuation: ^[32]

Future growth: earnings forecast to grow ~56% per year, with revenue up 16.3% over the last year.
Financial health: no balance‑sheet debt, but less than one year of cash runway at current burn rate.
Valuation: P/S ratio above 40x, and their DCF‑style intrinsic value model suggests the stock is hundreds of percent above its estimated fair value at $11.80.
Volatility: average weekly price swing of 13.5%, much higher than both the U.S. market and the medical‑equipment peer group.

Sete News arrives at similar numbers using raw fundamentals: Q3 revenue of $3.54 million, operating income of –$8.02 million, EBITDA of –$7.88 million, and diluted EPS of –$0.17. Analysts’ next‑quarter EPS estimate sits at –$0.12, pointing to ongoing, but slowly narrowing, losses. ^[33]

At the recent $11.80 close:

Market cap ≈ $552.8m.
TTM revenue ≈ $13.1m.
Implied P/S ≈ 42x, even higher than many large, profitable med‑tech names. ^[34]

Even if the stock traded back down to the $6 analyst consensus, the implied P/S would still be over 20x, which underlines how dependent the bull case is on rapid growth and future pipeline success rather than current cash flows.

Key risks for CV stock

Recent research and news coverage highlight several risk factors investors are wrestling with:

High volatility and technical risk
- Average weekly moves >13% and day‑to‑day swings above 30% place CV firmly in “high‑beta micro‑cap” territory. ^[35]
- A December 11 update on Simply Wall St explicitly flags share‑price stability as a new minor risk. ^[36]
Short operating runway and potential dilution
- Cash of $17.8m at quarter‑end versus $15.2m of operating cash outflows over the first nine months of 2025 implies limited runway unless growth accelerates or spending slows. ^[37]
- With no debt, future growth capital is likely to come from equity issuance, which could dilute existing shareholders.
Post‑IPO lockup expiration
- RTTNews notes that the IPO lockup expires on December 29, 2025, opening the door for pre‑IPO investors and insiders to sell. ^[38]
- For a stock that has more than doubled in a month, lockup expiry can act as a significant overhang.
Execution and regulatory risk
- Breakthrough Device Designation for the pancreatic‑cancer capsule is not guaranteed, and even if granted, commercialization will take years and require additional capital. ^[39]
- The same applies to colon‑capsule and other pipeline programs; clinical and regulatory setbacks are common in med‑tech.
Valuation vs. fundamentals
- MarketBeat’s December 9 piece frames CV as a “Moderate Buy” with an average $6 target and notes that Q3 EPS and revenue missed expectations, underscoring that the stock’s recent performance is driven more by narrative and positioning than by a clean beat‑and‑raise quarter. ^[40]

Upcoming catalysts to watch

Based on current guidance and third‑party data, key milestones for CapsoVision over the next 6–12 months include:

Next earnings report – TradingView lists February 25, 2026 as the next expected earnings date (subject to change by the company). ^[41]
Lockup expiration – December 29, 2025, when IPO insiders can begin selling shares. ^[42]
Regulatory updates – Any FDA feedback on the Breakthrough Device Designation application for the pancreatic‑cancer capsule and progress on the colon‑capsule program. ^[43]
Additional investor conferences or coverage – Following the Benchmark Discovery conference, more small‑cap and med‑tech conferences could expand institutional awareness. ^[44]

Investors and traders are likely to react sharply—up or down—to each of these events given the stock’s current positioning.

How the market is framing CapsoVision now

Recent commentary from TS2 and MarketBeat places CapsoVision squarely in the “AI + healthcare micro‑cap” bucket that has captivated parts of the market in 2025. A December 9 roundup of U.S. top gainers explicitly lists CapsoVision as continuing its “post‑IPO ascent” on the back of Q2 and Q3 results and the narrative around AI‑enabled capsule endoscopy. TechStock²+1

Put simply:

The bull story leans on accelerating adoption of CapsoCam Plus, a differentiated capsule‑and‑cloud platform, expansion into colon and pancreatic indications, and a growing AI analytics layer that could improve detection rates and workflow efficiency. ^[45]
The bear story focuses on thin revenue, heavy losses, limited cash, and a share price that has outrun even the most optimistic published price targets by a wide margin. ^[46]

For now, the market is voting with volume rather than spreadsheets—but as lockups expire and the next round of data and earnings arrives, that balance can shift quickly.

Bottom line

As of December 11, 2025, CapsoVision is:

A newly public, loss‑making capsule endoscopy specialist with a credible GI‑focused product platform.
A stock that has rallied triple‑digits in weeks, trading at >40x sales and far above a $5–7 analyst price‑target range.
A name where AI, med‑tech and small‑float momentum intersect—offering potentially large upside and equally dramatic downside.

Nothing in this article is investment advice, but the message from current news and forecasts is clear: CV is now a high‑risk, high‑reward story stock, where future returns are likely to be driven as much by execution and regulatory outcomes as by the technical forces that just sent it parabolic.